Bionano Genomics Selected For Sole Source Contract By NIH For Optical Genome Mapping Reagents And Instruments; No Contract Value Disclosed

https://sam.gov/opp/7a19a6e8954c4de1a128b841e2018400/view

Description

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

This procurement is for reagents for the Bionano Optical Genome Mapping (OGM) assay for testing samples from patient. Bionano OGM instrument and assay are used to perform optical genome mapping of patient samples to detect chromosomal, cytogenetic, and structural abnormalities that are often missed by other molecular technologies such as cytogenetics, fluorescence in situ hybridization (FISH), or next generation sequencing (NGS).

Bionano is the original reagent manufacturer and sole vendor for instruments of these kinds of tests, i.e., optical genome mapping to detect large deletions and cytogenetic abnormalities, copy number abnormalities, and small structural variants from patient samples. It is advisable to use OGM for testing of samples from patients with cancer, cancer predisposing disorders, and with complicated clinical and pathological phenotypes. Furthermore, the instrument obtained from the vendor will be available to other researchers in the Clinical Center and potentially validated for clinical testing purposes.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.